Board of Directors

  • Julian Baker, Managing Partner, Lead Independent Director, Baker Brothers Investments
  • Felix Baker, Ph.D., Managing Partner, Baker Brothers Investments
  • Fred Cohen, M.D., D.Phil., Partner, TPG
  • Henry J. Fuchs, M.D., Executive Vice President and Chief Medical Officer, BioMarin Pharmaceutical Inc.
  • Ginger L. Graham, President and CEO, Two Trees Consulting and former President and CEO, Amylin Pharmaceuticals
  • Randall Livingston, Vice President for Business Affairs and Chief Financial Officer, Stanford University
  • Kimberly J. Popovits (Inside Director), Chairman of the Board, Chief Executive Officer & President

Julian Baker, Managing Partner, Lead Independent Director, Baker Brothers Investments

Julian Baker has served as a director of Genomic Health since January 2001. Mr. Baker is a managing partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker’s firm manages a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family, now known as Baker/Tisch investments. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. He is also a director of Incyte Corporation, Neurogen Corporation, Theravance, Inc. and Trimeris, Inc. Mr. Baker holds an A.B. in Social Studies from Harvard University.

Felix Baker, Ph.D., Managing Partner, Baker Brothers Investments

Felix J. Baker, Ph.D., has served as a director of Genomic Health since 2012 .  Felix J. Baker is a Managing Partner of Baker Brothers Investments, which he and his brother, Company director Julian C. Baker, founded in 2000. Dr. Baker’s firm manages a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Dr. Baker’s career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. Dr. Baker currently serves as a director of Seattle Genetics, Inc. and Synageva BioPharma Corp., both of which are publicly-traded biotechnology companies.

Fred Cohen, M.D., D.Phil., Partner, TPG

Fred Cohen, M.D., D.Phil., has served as a director of Genomic Health since April 2002. Dr. Cohen is a partner at TPG, a venture capital firm which he joined in 2001.  Dr. Cohen is also a Professor of Medicine and Pharmacology at the University of California, San Francisco, where he has taught since July 1988. Dr. Cohen is a director of Matrix Laboratories Ltd., BioCryst Pharmaceuticals, Inc. and a number of privately held companies. Dr. Cohen holds a B.S. from Yale University, a Ph.D. from Oxford University and an M.D. from Stanford University.

Henry J. Fuchs, M.D., Executive Vice President and Chief Medical Officer, BioMarin Pharmaceutical Inc.

Henry J. Fuchs, M.D, has served as a director of Genomic Health since September 2013. Dr. Fuchs is the Executive Vice President and Chief Medical Officer of BioMarin Pharmaceutical Inc., a biopharmaceutical company. From September 2005 to December 2008, Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company. From October 1996 until June 2005, Dr. Fuchs served in multiple roles of increasing responsibility at Ardea Biosciences, Inc., a biotechnology company, first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as President and Chief Executive Officer. From 1987 to 1996, Dr. Fuchs held various positions at Genentech Inc., a biotechnology company. Dr. Fuchs serves as a director of Mirati Therapeutics, Inc. and served as a director of Ardea Biosciences, Inc. from November 2001 to June 2012. Dr. Fuchs received a B.A. in Biochemical Sciences from Harvard University, and an M.D. from George Washington University.

Ginger L. Graham, President and CEO, Two Trees Consulting and former President and CEO, Amylin Pharmaceuticals

Ginger L. Graham has served as a director of Genomic Health since 2008.  Ms. Graham is a member of the Harvard Business School Health Industry Alumni Advisory Board, The University of Arkansas Chancellor’s Campaign Steering Committee, and the Advisory Board for the BioFrontiers Institute at the University of Colorado.  She is also a director of Walgreen Co., the Proteus Digital Health Pharmaceutical Division, Surefire Medical, Elcelyx Therapeutics, and the Circle of Life Hospice Foundation.  Ms. Graham serves on the Advisory Board for the Kellogg Center for Executive Women and co-chairs the Scientific Council of the University of Colorado’s Center for Women’s Health Research.

Randall Livingston, Vice President for Business Affairs and Chief Financial Officer, Stanford University

Randall Livingston has served as a director of Genomic Health since October 2004. In 2001, Mr. Livingston was appointed Vice President for Business Affairs and Chief Financial Officer of Stanford University. From 1999 to 2001, Mr. Livingston served as Executive Vice President and Chief Financial Officer of OpenTV Corp., a provider of interactive television services. From 1996 until 1999, Mr. Livingston served as a consultant and part-time executive for several Silicon Valley technology companies. Prior to 1996, Mr. Livingston worked for Heartport, Inc., Taligent, Apple Computer, Ingres Corporation and McKinsey & Company. Mr. Livingston holds a B.S. in Mechanical Engineering from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Kimberly J. Popovits, Chairman of the Board, Chief Executive Officer & President

Committed to changing the paradigm of cancer care, Kim Popovits has served as Chairman of the Board since 2012, Chief Executive Officer and President since 2009 and as President and Chief Operating Officer since 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at Genentech, Inc., a biotechnology company, dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim holds a Bachelor of Arts degree in Business from Michigan State University. Kim currently serves on the board of BayBio, Northern California's life science association, which supports the regional bioscience community through advocacy, enterprise support, and enhancement of research collaboration. Kim is also the President of The Coalition for 21st Century Medicine, whose mission is to improve the quality of healthcare by encouraging research, development and commercialization of innovative diagnostic technologies that will personalize patient care, improve patient outcomes and reduce healthcare costs. She most recently joined the board of the American Clinical Laboratory Association (ACLA) and serves as an Advisor to the Healthcare Businesswomen’s Association (HBA). Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including, being named as the Woman of the Year in 2008 by the Women Health Care Executives and as one of the Most Influential Women in the Bay Area by The San Francisco Business Times from 2006 - 2012.